KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Receivables (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Change in Receivables for 16 consecutive years, with $90.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 298.39% to $90.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $128.1 million, a 72.49% increase, with the full-year FY2025 number at $128.1 million, up 72.49% from a year prior.
  • Change in Receivables was $90.5 million for Q4 2025 at Halozyme Therapeutics, up from $29.7 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $90.5 million in Q4 2025 to a low of -$41.1 million in Q3 2021.
  • A 5-year average of $14.1 million and a median of $14.3 million in 2023 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 746.9% in 2021; the steepest drop was 263.41% in 2021.
  • Halozyme Therapeutics' Change in Receivables stood at -$21.1 million in 2021, then skyrocketed by 136.71% to $7.8 million in 2022, then soared by 117.73% to $16.9 million in 2023, then soared by 34.51% to $22.7 million in 2024, then surged by 298.39% to $90.5 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Change in Receivables are $90.5 million (Q4 2025), $29.7 million (Q3 2025), and $11.7 million (Q2 2025).